Bleakley Financial Group LLC Acquires New Stake in United Therapeutics Co. (NASDAQ:UTHR)

Bleakley Financial Group LLC bought a new position in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 670 shares of the biotechnology company’s stock, valued at approximately $240,000.

Other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares in the last quarter. LSV Asset Management grew its stake in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after buying an additional 22,683 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares in the last quarter. Finally, Swedbank AB bought a new stake in shares of United Therapeutics during the 1st quarter worth $97,316,000. 94.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $337.40, for a total transaction of $1,214,640.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $43,862. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $337.40, for a total transaction of $1,214,640.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $43,862. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 106,412 shares of company stock worth $36,470,922. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Stock Down 4.8 %

Shares of NASDAQ:UTHR opened at $352.58 on Thursday. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $377.03. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The stock’s 50-day moving average is $352.33 and its 200 day moving average is $310.92. The company has a market cap of $15.69 billion, a PE ratio of 16.20, a P/E/G ratio of 1.34 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.24 EPS. Sell-side analysts anticipate that United Therapeutics Co. will post 24.72 EPS for the current year.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. UBS Group raised their price target on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. HC Wainwright restated a “buy” rating and issued a $400.00 price objective on shares of United Therapeutics in a report on Thursday, August 1st. Finally, Oppenheimer increased their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $361.33.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.